These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17035667)

  • 21. The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1.
    Prakesch M; Denisov AY; Naim M; Gehring K; Arya P
    Bioorg Med Chem; 2008 Aug; 16(15):7443-9. PubMed ID: 18603434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Discovering high-affinity ligands for proteins: SAR by NMR].
    Kamisuki S; Uesugi M
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1818-9. PubMed ID: 18051441
    [No Abstract]   [Full Text] [Related]  

  • 23. Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors.
    Mor M; Rivara S; Lodola A; Lorenzi S; Bordi F; Plazzi PV; Spadoni G; Bedini A; Duranti A; Tontini A; Tarzia G
    Chem Biodivers; 2005 Nov; 2(11):1438-51. PubMed ID: 17191945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
    ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fragment-based screening: a promising avenue for drug design].
    Krimm I
    Med Sci (Paris); 2015 Feb; 31(2):197-202. PubMed ID: 25744267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cracking the molecular weight barrier: fragment screening of an aminotransferase using an NMR-based functional assay.
    Mendoza R; Petros AM; Liu Y; Thimmapaya R; Surowy CS; Leise WF; Pereda-Lopez A; Panchal SC; Sun C
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5248-50. PubMed ID: 21840712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Communication breakdown: protein dynamics and drug design.
    Peng JW
    Structure; 2009 Mar; 17(3):319-20. PubMed ID: 19278644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
    Pirard B
    Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
    Stebbins JL; Zhang Z; Chen J; Wu B; Emdadi A; Williams ME; Cashman J; Pellecchia M
    J Med Chem; 2007 Dec; 50(26):6607-17. PubMed ID: 18038971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
    Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
    J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
    Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.
    Smits RA; Lim HD; Hanzer A; Zuiderveld OP; Guaita E; Adami M; Coruzzi G; Leurs R; de Esch IJ
    J Med Chem; 2008 Apr; 51(8):2457-67. PubMed ID: 18357976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor.
    Heckmann D; Meyer A; Laufer B; Zahn G; Stragies R; Kessler H
    Chembiochem; 2008 Jun; 9(9):1397-407. PubMed ID: 18481343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of novel histone deacetylase inhibitors.
    Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2.
    Marcaurelle LA; Johannes C; Yohannes D; Tillotson BP; Mann D
    Bioorg Med Chem Lett; 2009 May; 19(9):2500-3. PubMed ID: 19329314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationship anatomy by network-like similarity graphs and local structure-activity relationship indices.
    Wawer M; Peltason L; Weskamp N; Teckentrup A; Bajorath J
    J Med Chem; 2008 Oct; 51(19):6075-84. PubMed ID: 18798611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The design of inhibitors for medicinally relevant metalloproteins.
    Jacobsen FE; Lewis JA; Cohen SM
    ChemMedChem; 2007 Feb; 2(2):152-71. PubMed ID: 17163561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.